Table 3.
Characteristics of RCTs
| Study, Year | Location | Study Design | Follow‐Up Period | Age (Mean), y | Outcome | Outcome Assessment | Type of Statins | Cases/Statins Group | Cases/Control Group |
|---|---|---|---|---|---|---|---|---|---|
| Laties, 199123 | US | RCT | 48 weeks | 18 to 70 (<60) | Cataract surgery | Slit‐lamp examination | Lovastatin | 25/6582 | 7/1663 |
| Harris, 199524 | EU | RCT | 18 months | 40 to 75 (>60) | Cataract and Cataract surgery | OXGRAE | Simvastatin | 30/414 | 10/207 |
| Pederson, 199625 | EU | RCT | 5.4 years | 35 to 70 (>60) | Cataract | Slit‐lamp examination | Simvastatin | 66/2221 | 53/2223 |
| Heart protection study, 200226 | US | RCT | 5 years | 40 to 80 (NA)a | Cataract | Medical records | Simvastatin | 393/10 232 | 404/10 237 |
| Bang, 201527 | US | RCT | 4.3 years | 45 to 85 (>60) | Cataract | Medical records | Simvastatin plus Ezetimibe | NA/944b | NA/929b |
RCTs indicates randomized controlled trials; NA indicates not available; OXGRADE, Oxford grading system.
a
The authors did not show the mean age of subjects.
b
The authors showed the relative risk value instead of number of cases.